The Bcl-2-related survival proteins confer cellular resistance to a wide range of apoptosis-inducing agents. In work can-led out in our labs, a novel small molecular ligand to the Bcl-xL protein has been identified, which inhibits the molecular pore function of Bcl-xL and selectively kills Bcl-xL and, at higher doses, Bcl neg2-expressing cells. We made the initial observation that Bcl-xL-expressing hepatocyte cell lines are more sensitive than isogenic control cells to antimycin A (AA), a known inhibitor of mitochondrial electron transport. A 2-methoxy antimycin A analog lacking effects on mitochondrial respiration still exhibited selective toxicity for Bcl-xL plus cells and mitochondria. Computational molecular docking analysis predicted that antimycin A conforms to a conserved hydrophobic groove on the molecular surface of Bcl-xL. We confirmed this interaction by showing competitive binding of AA and its 2-methoxy derivative with a known hydrophobic groove ligand to recombinant Bcl-xL and Bcl-2 proteins, a BH3 domain peptide derived from the pro-apoptotic dimerization partner, Bak. Finally, we found that AA inhibits the pore-forming activity of Bcl-xL in synthetic Liposomes, demonstrating that this small ligand can directly inhibit the function of Bcl-2-related survival proteins.
Two aims of this application investigate the structural determinants of AA binding to the Bcl-xL hydrophobic pocket and mechanism of pore inhibition. Initial screening of human hematopoietic cell lines for cytotoxic effects of antimycin A indicates myeloma cell lines, including multi-drug resistant sublines, are sensitive to AA and 2-methoxy AA. Several published studies have shown that myeloma cell survival is predominantly dependent on Bcl-xL, despite the expression of several related anti-apoptotic proteins. We propose, using pre-clinical models, to test whether multiple myeloma is particularly susceptible to Bcl-xL -targeted therapies, and validate Bcl-xL as the relevant target of 2-methoxy AA in myeloma cells, The questions to be addressed In three specific alms are as follows:
Specific Aims : 1. Evaluate efficacy and toxicology of 2-methoxy antimycin A3 in mouse myeloma and hepatoma tumor models. 2. Characterize biochemical mechanism of antimycin A inhibition of Bcl-,xL pore-forming function, including analysis of mutations in Bcl-xL hydrophobic groove binding site; x-ray crystallography of antimycin complex with Bcl-xL; and membrane topology studies. 3. Determine the role of endogenous pro-apoptotic dimer partners of Eel-if in the cytotoxic mechanism of antimycin A.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J3))
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Susnow, Nathan; Zeng, Liyun; Margineantu, Daciana et al. (2009) Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol 19:42-9
Schwartz, Pamela S; Hockenbery, David M (2007) Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA. Cancer Biol Ther 6:465-6
Schwartz, Pamela S; Manion, Michael K; Emerson, Christine B et al. (2007) 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol Cancer Ther 6:2073-80
O'Neill, Jason W; Manion, Michael K; Maguire, Brendan et al. (2006) BCL-XL dimerization by three-dimensional domain swapping. J Mol Biol 356:367-81
Erxleben, Holger A; Manion, Michael K; Hockenbery, David M et al. (2004) A novel approach for monitoring extracellular acidification rates: based on bead injection spectrophotometry and the lab-on-valve system. Analyst 129:205-12
Manion, Michael K; O'Neill, Jason W; Giedt, Chris D et al. (2004) Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem 279:2159-65